An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 3, 2014, Pages 248-260

  Ito, Ryo ^a   Satoh Asahara, Noriko ^a   Yamakage, Hajime ^a   Sasaki, Yousuke ^a   Odori, Shinji ^a   Kono, Shigeo ^a   Wada, Hiromichi ^a   Suganami, Takayoshi ^b   Ogawa, Yoshihiro ^b   Hasegawa, Koji ^a   Shimatsu, Akira ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Arterial stiffness; Cardio ankle vascular index; Eicosapentaenoic acid; EPA AA ratio; Obesity

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY ACID ANALYSIS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; WAIST CIRCUMFERENCE; AGED; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; PATHOPHYSIOLOGY;

ADULT; AGED; ARACHIDONIC ACID; CASE-CONTROL STUDIES; COHORT STUDIES; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; VASCULAR STIFFNESS;

EID: 84897059442     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.19976     Document Type: Article

References (56)

1. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE: Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA, 2002; 287: 1815-1821
2. GISSI-Prevenzione Investigators: Dietary supplementa tion with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet, 1999; 354: 447-455
3. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet, 2003; 361: 477-485
4. Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, Nagai R: Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoEdeficient mice. Atherosclerosis, 2008; 197: 524-533
5. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis, 2008; 197: 12-24
6. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098
7. Satoh N, Shimatsu A, Kotani K, Sakane N, Yamada K, Suganami T, Kuzuya H, Ogawa Y: Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and CRP in metabolic syndrome. Diabetes Care, 2007; 30: 144-146
8. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takeya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y: Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol, 2007; 27: 1918-1925
9. Yamada H, Yoshida M, Nakano Y, Suganami T, Satoh N, Mita T, Azuma K, Itoh M, Yamamoto Y, Kamei Y, Horie M, Watada H, Ogawa Y: In vivo and In vitro Inhibition of Monocyte Adhesion to Endothelial Cells and Endothelial Adhesion Molecules by Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol, 2008; 28: 2173-2179
10. Satoh N, Shimatsu A, Kotani K, Himeno A, Majima T, Yamada K, Suganami T, Ogawa Y: Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res, 2009; 32: 1004-1008
11. Calder PC: The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res, 2012; 56: 1073-1080
12. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet, 1978; 2: 117-119
13. Nakamura T, Azuma A, Kuribayashi T, Sugihara H, Okuda S, Nakagawa M: Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study. Br J Nutr, 2003; 89: 267-272
14. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators: Incremental effects of eicosapentaenoic acid on cardiovascular events in statintreated patients with coronary artery disease. Circ J, 2009; 73: 1283-1290
15. Ueeda M, Doumei T, Takaya Y, Shinohata R, Katayama Y, Ohnishi N, Takaishi A, Miyoshi T, Hirohata S, Kusachi S: Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J, 2008; 72: 1836-1843
16. Satoh-Asahara N, Shimatsu A, Sasaki Y, Nakaoka H, Himeno A, Tochiya M, Kono S, Takaya T, Ono K, Wada H, Suganami T, Hasegawa K, Ogawa Y: Highly purified eicosapentaenoic Acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care, 2012; 35: 2631-2639
17. Wang TM, Chen CJ, Lee TS, Chao HY, Wu WH, Hsieh SC, Sheu HH, Chiang AN: Docosahexaenoic acid attenuates VCAM-1 expression and NF-κB activation in TNF-α-treated human aortic endothelial cells. Journal of Nutritional Biochemistry, 2011; 22: 187-194
18. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA: Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol, 2006; 63: 1545-50.
19. Gorjão R, Azevedo-Martins AK, Rodrigues HG, Abdulkader F, Arcisio-Miranda M, Procopio J, Curi R: Comparative effects of DHA and EPA on cell function. Pharmacol Ther, 2009; 122: 56-64
20. Sekikawa A, Kadowaki T, El-Saed A, Okamura T, Sutton-Tyrrell K, Nakamura Y, Evans RW, Mitsunami K, Edmundowicz D, Nishio Y, Nakata K, Kadota A, Otake T, Miura K, Choo J, Abbott RD, Kuller LH, Curb JD, Ueshima H; ERA JUMP Study group: Differential association of docosahexaenoic and eicosapentaenoic acids with carotid intima-media thickness. Stroke, 2011; 42: 2538-2543
21. Hino A, Adachi H, Toyomasu K, Yoshida N, Enomoto M, Hiratsuka A, Hirai Y, Satoh A, Imaizumi T: Very long chain N-3 fatty acids intake and carotid atherosclerosis: an epidemiological study evaluated by ultrasonography. Atherosclerosis, 2004; 176: 145-149
22. Lindqvist HM, Sandberg AS, Fagerberg B, Hulthe J: Plasma phospholipid EPA and DHA in relation to atherosclerosis in 61-year-old men. Atherosclerosis, 2009; 205: 574-578
23. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC: Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis, 2010; 212: 252-259
24. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators: Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb, 2011; 18: 99-107
25. Ishiguro J, Tada T, Ogihara T, Ohzawa N, Murakami K, Kosuzume H: Metabolic disposition of ethyl eicosapentaenoate and its metabolites in rats and dogs. J Pharmacobiodyn, 1988; 11: 251-261
26. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke, 2008; 39: 2052-2058
27. Mishina M, Kim K, Kominami S, Mizunari T, Kobayashi S, Katayama Y: Impact of polyunsaturated fatty acid consumption prior to ischemic stroke. Acta Neurol Scand, 2013; 127: 181-185
28. Satoh N, Shimatsu A, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Ooishi M, Kotani K, Ogawa Y; For The Japan Obesity and Metabolic Syndrome Study (JOMS) Group: Evaluation of cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. Hypertens Res, 2008; 31: 1921-1930
29. Expert Panel on detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
30. International clinical harmonization of hemoglobin A1c in Japan: From JDS to NGSP values The report from "The Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing" of Japan Diabetes Society (JDS) [article online], 2012. Available: http://www. jds.or.jp/jds_or_jp0/uploads/photos/813.pdf. Accessed 4 February 2012.
31. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb, 2006; 13: 101-107
32. Yamakawa K, Shimabukuro M, Higa N, Asahi T, Ohba K, Arasaki O, Higa M, Oshiro Y, Yoshida H, Higa T, Saito T, Ueda S, Masuzaki H, Sata M: Eicosapentaenoic Acid supplementation changes Fatty Acid composition and corrects endothelial dysfunction in hyperlipidemic patients. Cardiol Res Pract, 2012; doi: 10.1155/2012/754181.
33. Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, Iwabuchi M, Ueeda M, Nobuyoshi M: Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J, 2012; 76: 423-429
34. Inoue K, Kishida K, Hirata A, Funahashi T, Shimomura I: Low serum eicosapentaenoic acid / arachidonic acid ratio in male subjects with visceral obesity. Nutr Metab, 2013; 10: 25
35. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS: The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. J Atheroscler Thromb, 2012; 19: 673-679
36. Ishida T, Ohta M, Nakakuki M, Kami H, Uchiyama R, Kawano H, Notsu T, Imada K, Shimano H: Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: Participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids, 2013; 88: 281-288
37. Decsi T, Csábi G, Török K, Erhardt E, Minda H, Burus I, Molnár S, Molnár D: Polyunsaturated fatty acids in plasma lipids of obese children with and without metabolic cardiovascular syndrome. Lipids, 2000; 35: 1179-1184
38. Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, Shimizu T, Hirose T, Tanaka Y, Kawamori R: Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis, 2007; 191: 162-167
39. Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M, Tanaka M, Yonezawa T, Ogawa H, Matsuzaki M; ELIA study group: Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study. J Atheroscler Thromb, 2011; 18: 857-866
40. Haiden M, Miyasaka Y, Kimura Y, Tsujimoto S, Maeba H, Suwa Y, Iwasaka T, Shiojima I: Effect of eicosapentaenoic acid on regional arterial stiffness: Assessment by tissue Doppler imaging. World J Cardiol, 2012; 4: 256-259
41. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H: Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J, 2008; 72: 598-604
42. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med, 1999; 340: 14-22
43. Gao L, Yin H, Milne GL, Porter NA, Morrow JD: Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem, 2006; 281: 14092-14099
44. Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab, 2011; 96: 3448-3456
45. Jia EZ, An FH, Liu P, Li F, Mao HW, Cui WJ, Xu HY: Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors: a multi-ethnic study. Intern Med, 2012; 51: 537-543
46. Relf IR, Lo CS, Myers KA, Wahlqvist ML: Risk factors for changes in aorto-iliac arterial compliance in healthy men. Arteriosclerosis, 1986; 6: 105-108
47. Weng C, Yuan H, Tang X, Huang Z, Yang K, Chen W, Yang P, Chen Z, Chen F: Age-and gender dependent association between components of metabolic syndrome and subclinical arterial stiffness in a Chinese population. Int J Med Sci, 2012; 9: 730-737
48. Ferrara LA, Mancini M, Celentano A, Galderisi M, Iannuzzi R, Marotta T, Gaeta I: Early changes of the arterial carotid wall in uncomplicated primary hypertensive patients. Study by ultrasound high-resolution B-mode imaging. Arterioscler Thromb, 1994; 14: 1290-1296
49. Lewis TV, Dart AM, Chin-Dusting JP: Endotheliumdependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J Am Coll Cardiol, 1999; 33: 805-812
50. Sundström J, Lind L, Nyström N, Zethelius B, Andrén B, Hales CN, Lithell HO: Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation, 2000; 101: 2595-2600
51. Nagashima H, Endo M: Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels, 2011; 26: 428-434
52. Okamura T, Moriyama Y, Kadowaki T, Kanda H, Ueshima H: Non-invasive measurement of brachial-ankle pulse wave velocity is associated with serum C-reactive protein but not with alpha-tocopherol in Japanese middle-aged male workers. Hypertens Res, 2004; 27:173-180
53. Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG: Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr, 2011; 93: 243-252
54. Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K: Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb, 2009; 16: 539-545
55. Hayakawa S, Yoshikawa D, Ishii H, Tanaka M, Kumagai S, Matsumoto M, Hayashi M, Sugiura T, Hayashi K, Ando H, Amano T, Murohara T: Association of plasma ω-3 to ω-6 polyunsaturated fatty acid ratio with complexity of coronary artery lesion. Intern Med, 2012; 51: 1009-1014
56. Ninomiya T, Doi Y, Kiyohara Y: Relationship between the ratio of serum eicosapentaenoic acid to arachidonic acid and the risk of death: the Hisayama Study. Circulation, 2011; 124: A8169